Research programme: bispecific oncology antibodies - NovImmune

Drug Profile

Research programme: bispecific oncology antibodies - NovImmune

Alternative Names: CD47/MSLN antibodies; mesothelin/CD47 bispecific antibodies; NI 1601; NI 1701; NI 1801; NIBX-2101; TG-1801

Latest Information Update: 27 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NovImmune SA
  • Developer NovImmune SA; Shire
  • Class Antineoplastics; Bispecific antibodies; Blood coagulation factors
  • Mechanism of Action CD19 antigen inhibitors; CD47 antigen inhibitors; Factor IXa inhibitors; Factor X inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Haemophilia A; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 27 Jun 2018 TG 1801 is still in preclinical trials for Non-Hodgkin's lymphoma in Switzerland
  • 27 Jun 2018 TG 1801 is still in preclinical trials for Precursor cell lymphoblastic leukaemia-lymphoma in Switzerland
  • 20 Jun 2018 Novimmune and TG Therapeutics agree to co-promote and co-develop TG 1801 worldwide for non-Hodgkin's lymphoma and precursor cell lymphoblastic leukaemia-lymphoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top